What has Karonga taught us? Tuberculosis studied over three decades

International Journal of Tuberculosis and Lung Disease

Volumn 13, Issue 2, 2009, Pages 153-164

  Crampin, Amelia C ^a,b   Glynn, J R ^a   Fine, P E M ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b KARONGA PREVENTION STUDY   (Malawi)

Author keywords

Epidemiology; Immunology; Malawi; Review; Tuberculosis

Indexed keywords

ANTIRETROVIRUS AGENT; BCG VACCINE; BIOLOGICAL MARKER; COTRIMOXAZOLE;

AFRICA; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACTERIAL TRANSMISSION; CLINICAL TRIAL; CONTACT EXAMINATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOTHERAPY; INCIDENCE; LEPROSY; LUNG TUBERCULOSIS; MALAWI; MOLECULAR EPIDEMIOLOGY; MORTALITY; MYCOBACTERIOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RECURRENT INFECTION; SEX DIFFERENCE; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ANTITUBERCULAR AGENTS; BCG VACCINE; CLINICAL PROTOCOLS; COMORBIDITY; DRUG THERAPY, COMBINATION; GENETIC PREDISPOSITION TO DISEASE; HIV INFECTIONS; HUMANS; MALAWI; MYCOBACTERIUM TUBERCULOSIS; PREVENTIVE HEALTH SERVICES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; RURAL HEALTH; RURAL HEALTH SERVICES; SEX FACTORS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; VACCINATION;

EID: 59549090622     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (87)

1. Ponnighaus J M, Fine P E, Bliss L, et al. The Karonga Prevention Trial: a leprosy and tuberculosis vaccine trial in northern Malawi. I. Methods of the vaccination phase. Lepr Rev 1993; 64: 338-356.
2. Ponnighaus J M, Fine P E, Maine N, Bliss L, Kalambo M, Ponnighaus I. The Lepra Evaluation Project (LEP), an epidemiological study of leprosy in northern Malawi. II: Prevalence rates. Lepr Rev 1988; 59: 97-112.
3. Glynn J R, Ponnighaus J, Crampin A C, et al. The development of the HIV epidemic in Karonga District, Malawi. AIDS 2001; 15: 2025-2029.
4. Crampin A C, Glynn J R, Ngwira B M, et al. Trends and measurement of HIV prevalence in northern Malawi. AIDS 2003; 17: 1817-1825.
5. White R G, Vynnycky E, Glynn J R, et al. HIV epidemic trend and antiretroviral treatment need in Karonga District, Malawi. Epidemiol Infect 2007; 135: 922-932.
6. Fine P E, Bruce J, Ponnighaus J M, Nkhosa P, Harawa A, Vynnycky E. Tuberculin sensitivity: conversions and reversions in a rural African population. Int J Tuberc Lung Dis 1999; 3: 962-975.
7. Floyd S, Ponnighaus J M, Bliss L, et al. BCG scars in northern Malawi: sensitivity and repeatability of scar reading, and factors affecting scar size. Int J Tuberc Lung Dis 2000; 4: 1133-1142.
8. Black G F, Fine P E M, Warndorff D K, et al. Relationship between IFN-gamma and skin test responsiveness to Mycobacterium tuberculosis PPD in healthy, non-BCG-vaccinated young adults in Northern Malawi. Int J Tuberc Lung Dis 2001; 5: 664-672.
9. Nyboe J. Interpretation of tuberculosis infection age curves. Bull World Health Organ 1957; 17: 319-339.
10. Roelsgaard E, Iversen E, Blocher C. Tuberculosis in tropical Africa: an epidemiological study. Bull World Health Organ 1964; 30: 459-518.
11. Rieder H L. Methodological issues in the estimation of the tuberculosis problem from tuberculin surveys. Tubercle Lung Dis 1995; 76: 114-121.
12. Bosman M C, Swai O B, Kwamanga D O, Agwanda R, Idukitta G, Misljenovic O. National tuberculin survey of Kenya, 1986-1990. Int J Tuberc Lung Dis 1998; 2: 272-280.
13. Davies G R, Fine P E, Vynnycky E. Mixture analysis of tuberculin survey data from northern Malawi and critique of the method. Int J Tuberc Lung Dis 2006; 10: 1023-1029.
14. American Thoracic Society. Diagnostic standards and classification of tuberculosis and other mycobacterial diseases. Am Rev Respir Dis 1981; 123: 343-358.
15. Thompson N J, Glassroth J L, Snider D E Jr, Farer L S. The booster phenomenon in serial tuberculin testing. Am Rev Respir Dis 1979; 119: 587-597.
16. Grzybowski S, Allen E A. The challenge of tuberculosis in decline: a study based on the epidemiology of tuberculosis in Ontario, Canada. Am Rev Respir Dis 1964; 90: 707-720.
17. Baily G V. Tuberculosis prevention trial, Madras. Indian J Med Res 1980; 72 (Suppl): S1-S74.
18. Narain R, Nair S S, Chandrasekhar P, Rao G R. Problems connected with estimating the incidence of tuberculosis infection. Bull World Health Organ 1966; 34: 605-622.
19. Floyd S, Ponnighaus J M, Bliss L, et al. Kinetics of delayed-type hypersensitivity to tuberculin induced by bacille Calmette-Guerin vaccination in northern Malawi. J Infect Dis 2002; 186: 807-814.
20. Ota M O, Goetghebuer T, Vekemans J, et al. Dissociation between tuberculin skin test and in vitro IFN-gamma responses following neonatal BCG vaccination. J Trop Pediatr 2006; 52: 136-140.
21. Hill P C, Brookes R H, Fox A, et al. Large-scale evaluation of enzyme-linked immunospot assay and skin test for diagnosis of Mycobacterium tuberculosis infection against a gradient of exposure in The Gambia. Clin Infect Dis 2004; 38: 966-973.
22. van Embden J D, Cave M D, Crawford J T, et al. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol 1993; 31: 406-409.
23. Small P M, Hopewell P C, Singh S P, et al. The epidemiology of tuberculosis in San Francisco. A population-based study using conventional and molecular methods. N Engl J Med 1994; 330: 1703-1709.
24. Glynn J R, Bauer J, de Boer A S, et al. Interpreting DNA finger-print clusters of Mycobacterium tuberculosis. European Concerted Action on Molecular Epidemiology and Control of Tuberculosis. Int J Tuberc Lung Dis 1999; 3: 1055-1060.
25. Glynn J R, Crampin A C, Yates M D, et al. The importance of recent infection with Mycobacterium tuberculosis in an area with high HIV prevalence: a long-term molecular epidemiological study in Northern Malawi. J Infect Dis 2005; 192: 480-487.
26. Crampin A C, Glynn J R, Traore H, et al. Tuberculosis transmission attributable to close contacts and HIV status, Malawi. Emerg Infect Dis 2006; 12: 729-735.
27. Richardson M, Carroll N M, Engelke E, et al. Multiple Mycobacterium tuberculosis strains in early cultures from patients in a high-incidence community setting. J Clin Microbiol 2002; 40: 2750-2754.
28. Crampin A C, Floyd S, Ngwira B M, et al. Assessment and evaluation of contact as a risk factor for tuberculosis in rural Africa. Int J Tuberc Lung Dis 2008; 12: 612-618.
29. Wilkinson D, Pillay M, Crump J, Lombard C, Davies G R, Sturm A W. Molecular epidemiology and transmission dynamics of Mycobacterium tuberculosis in rural Africa. Trop Med Int Health 1997; 2: 747-753.
30. Schaaf H S, Michaelis I A, Richardson M, et al. Adult-to-child transmission of tuberculosis: household or community contact? Int J Tuberc Lung Dis 2003; 7: 426-431.
31. Nair S S, Ramanath Rao G, Chandresekhar P. Distribution of tuberculosis infection and disease in clusters in rural households. Indian J Tuberc 1971; 18: 3-9.
32. Lienhardt C, Fielding K, Sillah J, et al. Risk factors for tuberculosis infection in sub-Saharan Africa: a contact study in the Gambia. Am J Respir Crit Care Med 2003; 168: 448-455.
33. Glynn J R, Crampin A C, Traore H, et al. Mycobacterium tuberculosis Beijing genotype, northern Malawi. Emerg Infect Dis 2005; 11: 150-153.
34. Corbett E L, Marston B, Churchyard G J, De Cock K M. Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet 2006; 367: 926-937.
35. Ponnighaus J M, Mwanjasi L J, Fine P E, et al. Is HIV infection a risk factor for leprosy? Int J Lepr Other Mycobact Dis 1991; 59: 221-228.
36. Glynn J R, Crampin A C, Ngwira B M, et al. Trends in tuberculosis and the influence of HIV infection in northern Malawi, 1988-2001. AIDS 2004; 18: 1459-1463.
37. Glynn J R, Warndorff D K, Malema S S, et al. Tuberculosis: associations with HIV and socio-economic status in rural Malawi. Trans R Soc Trop Med Hyg 2000; 94: 500-503.
38. Crampin A C, Glynn J R, Floyd S, et al. Tuberculosis and gender: exploring the patterns in a case control study in Malawi. Int J Tuberc Lung Dis 2004; 8: 194-203.
39. Van den Broek J, Borgdorff M W, Pakker N G, et al. HIV-1 infection as a risk factor for the development of tuberculosis: a case-control study in Tanzania. Int J Epidemiol 1993; 22: 1159-1165.
40. Godfrey-Faussett P, Sonnenberg P, Shearer S C, et al. Tuberculosis control and molecular epidemiology in a South African gold-mining community. Lancet 2000; 356: 1066-1071.
41. Girardi E, Raviglione M C, Antonucci G, Godfrey-Faussett P, Ippolito G. Impact of the HIV epidemic on the spread of other diseases: the case of tuberculosis. AIDS 2000; 14 (Suppl 3): S47-S56.
42. Yang Z H, Mtoni I, Chonde M, et al. DNA fingerprinting and phenotyping of Mycobacterium tuberculosis isolates from human immunodeficiency virus (HIV)-seropositive and HIV-seronegative patients in Tanzania. J Clin Microbiol 1995; 33: 1064-1069.
43. Lockman S, Sheppard J D, Braden C R, et al. Molecular and conventional epidemiology of Mycobacterium tuberculosis in Botswana: a population-based prospective study of 301 pulmonary tuberculosis patients. J Clin Microbiol 2001; 39: 1042-1047.
44. Easterbrook P J, Gibson A, Murad S, et al. High rates of clustering of strains causing tuberculosis in Harare, Zimbabwe: a molecular epidemiological study. J Clin Microbiol 2004; 42: 4536-4544.
45. Haas W H, Engelmann G, Amthor B, et al. Transmission dynamics of tuberculosis in a high-incidence country: prospective analysis by PCR DNA fingerprinting. J Clin Microbiol 1999; 37: 3975-3979.
46. Bruchfeld J, Aderaye G, Palme I B, et al. Molecular epidemiology and drug resistance of Mycobacterium tuberculosis isolates from Ethiopian pulmonary tuberculosis patients with and without human immunodeficiency virus infection. J Clin Microbiol 2002; 40: 1636-1643.
47. Glynn J R, Crampin A C, Traore H, et al. Determinants of cluster size in a large population based molecular epidemiology study of tuberculosis in northern Malawi. Emerg Infect Dis 2008; 14: 1060-1066.
48. Glynn J R, Warndorff D K, Fine P E, Munthali M M, Sichone W, Ponnighaus J M. Measurement and determinants of tuberculosis outcome in Karonga District, Malawi. Bull World Health Organ 1998; 76: 295-305.
49. Ciglenecki I, Glynn J R, Mwinga A, et al. Population differences in death rates in HIV-positive patients with tuberculosis. Int J Tuberc Lung Dis 2007; 11: 1121-1128.
50. Crampin A C, Mwaungulu J N, Mwaungulu F D, et al. Rates of relapse and reinfection in HIV-positive and -negative individuals with recurrent tuberculosis. 38th Union World Conference on Lung Health 2007, Cape Town, South Africa. Int J Tuberc Lung Disease 2007; 11 (Suppl): S 110 [Abstract PS 71256-10].
51. Kenyon T A, Creek T, Laserson K, et al. Risk factors for transmission of Mycobacterium tuberculosis from HIV-infected tuberculosis patients, Botswana. Int J Tuberc Lung Dis 2002; 6: 843-850.
52. Carvalho A C, DeRiemer K, Nunes Z B, et al. Transmission of Mycobacterium tuberculosis to contacts of HIV-infected tuberculosis patients. Am J Respir Crit Care Med 2001; 164: 2166-2171.
53. Elliott A M, Hayes R J, Halwiindi B, et al. The impact of HIV on infectiousness of pulmonary tuberculosis: a community study in Zambia. AIDS 1993; 7: 981-987.
54. Crampin A C, Floyd S, Mwaungulu F, et al. Comparison of two versus three smears in identifying culture-positive tuberculosis patients in a rural African setting with high HIV prevalence. Int J Tuberc Lung Dis 2001; 5: 994-999.
55. World Health Organization. Reduction of number of smears for the diagnosis of pulmonary TB. Geneva, Switzerland: WHO, 2008.
56. Ngwira B, Chagaluka S, Warndorff D, Branson K, Lucas S, Fine P. Development of a scoring system for the diagnosis of tuberculous lymphadenitis. Malawi Med J 2002; 13: 14-16.
57. Munthali L, Mwaungulu J N, Munthali K, Bowie C, Crampin A C. Using tuberculosis suspects to identify patients eligible for antiretroviral treatment. Int J Tuberc Lung Dis 2006; 10: 199-202.
58. Glynn J R, Jenkins P A, Fine P E, et al. Patterns of initial and acquired anti-tuberculosis drug resistance in Karonga District, Malawi. Lancet 1995; 345: 907-910.
59. Warndorff D K, Yates M, Ngwira B, et al. Trends in anti-tuberculosis drug resistance in Karonga District, Malawi, 1986-1998. Int J Tuberc Lung Dis 2000; 4: 752-757.
60. Mwaungulu F, Crampin A C, Chagaluka S, et al. Anti-tuberculous drug resistance in Karonga District: pattern and trend 1986-2001. Malawi Med J 2002; 13: 3-6.
61. Maher D, Nunn P. Evaluation and determinants of tuberculosis outcome. Point of view. Bull World Health Organ 1998; 76: 307-308.
62. Mwinga A, Nunn A, Ngwira B, et al. Mycobacterium vaccae (SRL172) immunotherapy as an adjunct to standard anti-tuberculosis treatment in HIV-infected adults with pulmonary tuberculosis: a randomised placebo-controlled trial. Lancet 2002; 360: 1050-1055.
63. Mwaungulu F B, Floyd S, Crampin A C, et al. Cotrimoxazole prophylaxis reduces mortality in human immunodeficiency virus-positive tuberculosis patients in Karonga District, Malawi. Bull World Health Organ 2004; 82: 354-363.
64. Wallace C, Clayton D. Estimating the relative recurrence risk ratio using a global cross-ratio model. Genet Epidemiol 2003; 25: 293-302.
65. Fitness J, Floyd S, Warndorff D K, et al. Large-scale candidate gene study of tuberculosis susceptibility in the Karonga district of northern Malawi. Am J Trop Med Hyg 2004; 71: 341-349.
66. Vannberg F O, Chapman S J, Khor C C, et al. CD209 genetic polymorphism and tuberculosis disease. PLoS ONE 2008; 3: e1388.
67. Ponnighaus J M, Fine P E, Sterne J A, et al. Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi. Lancet 1992; 339: 636-639.
68. Karonga Prevention Trial Group. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Lancet 1996; 348: 17-24.
69. Sterne J A, Fine P E, Ponnighaus J M, Sibanda F, Munthali M, Glynn J R. Does bacille Calmette-Guerin scar size have implications for protection against tuberculosis or leprosy? Tubercle Lung Dis 1996; 77: 117-123.
70. Fine P E, Ponnighaus J M, Maine N. The distribution and implications of BCG scars in northern Malawi. Bull World Health Organ 1989; 67: 35-42.
71. Ponnighaus J M, Fine P E. The Karonga prevention trial - which BCG? Lepr Rev 1986; 57 (Suppl 2): S285-S292.
72. Weir R E, Morgan A R, Britton W J, Butlin C R, Dockrell H M. Development of a whole blood assay to measure T-cell responses to leprosy: a new tool for immuno-epidemiological field studies of leprosy immunity. J Immunol Methods 1994; 176: 93-101.
73. Weir R E, Black G F, Dockrell H M, et al. Mycobacterial purified protein derivatives stimulate innate immunity: Malawians show enhanced tumor necrosis factor alpha, interleukin-1beta (IL-1beta), and IL-10 responses compared to those of adolescents in the United Kingdom. Infect Immun 2004; 72: 1807-1811.
74. Black G F, Weir R E, Floyd S, et al. BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies. Lancet 2002; 359: 1393-1401.
75. Black G F, Dockrell H M, Crampin A C, et al. Patterns and implications of naturally acquired immune responses to environmental and tuberculous mycobacterial antigens in northern Malawi. J Infect Dis 2001; 184: 322-329.
76. Black G F, Weir R E, Chaguluka S D, et al. Gamma interferon responses induced by a panel of recombinant and purified mycobacterial antigens in healthy, non-mycobacterium bovis BCG-vaccinated Malawian young adults. Clin Diagn Lab Immunol 2003; 10: 602-611.
77. Weir R E, Fine P E, Nazareth B, et al. Interferon-gamma and skin test responses of schoolchildren in southeast England to purified protein derivatives from Mycobacterium tuberculosis and other species of mycobacteria. Clin Exp Immunol 2003; 134: 285-294.
78. Weir R E, Black G F, Nazareth B, et al. The influence of previous exposure to environmental mycobacteria on the interferon-gamma response to bacille Calmette-Guerin vaccination in southern England and northern Malawi. Clin Exp Immunol 2006; 146: 390-399.
79. Bennett A R, Gorak-Stolinska P, Ben-Smith A, et al. The PPD-specific T-cell clonal response in UK and Malawian subjects following BCG vaccination: a new repertoire evolves over 12 months. Vaccine 2006; 24: 2617-2626.
80. Chilima B Z, Clark IM, Floyd S, Fine P E, Hirsch P R. Distribution of environmental mycobacteria in Karonga District, northern Malawi. Appl Environ Microbiol 2006; 72: 2343-2350.
81. Fine P E, Floyd S, Stanford J L, et al. Environmental mycobacteria in northern Malawi: implications for the epidemiology of tuberculosis and leprosy. Epidemiol Infect 2001; 126: 379-387.
82. Edwards L B, Acquaviva F A, Livesay V T. Identification of tuberculous infected. Dual tests and density of reaction. Am Rev Respir Dis 1973; 108: 1334-1339.
83. Fine P E, Sterne J A, Ponnighaus J M, Rees R J. Delayed-type hypersensitivity, mycobacterial vaccines and protective immunity. Lancet 1994; 344: 1245-1249.
84. McKinney J D, Jacobs W R, Bloom B R. Persisting problems in tuberculosis. In: Krause R M, ed. Emerging infections. New York, NY, USA: Academic Press, 1998: pp 51-146.
85. Brandt L, Feino Cunha J, Weinreich Olsen A, et al. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect Immun 2002; 70: 672-678.
86. Palmer C E, Long M W. Effects of infection with atypical mycobacteria on BCG vaccination and tuberculosis. Am Rev Respir Dis 1966; 94: 553-568.
87. Jahn A, Floyd S, Crampin A C, et al. Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in Malawi. Lancet 2008; 371: 1603-1611.